Status:
TERMINATED
Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict...
Detailed Description
OBJECTIVES: Primary * Correlate plasma and urine vascular endothelial growth factor (VEGF) levels with survival duration in patients with advanced hormone-refractory adenocarcinoma of the prostate p...
Eligibility Criteria
Inclusion
- Registration to CALGB 9480 or 9583
- Samples collected and shipped appropriately
- Institutional Review Board (IRB) review and approval at the institution where the laboratory work will be performed is required
Exclusion
Key Trial Info
Start Date :
July 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2016
Estimated Enrollment :
868 Patients enrolled
Trial Details
Trial ID
NCT00898833
Start Date
July 1 2003
End Date
June 1 2016
Last Update
August 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001